Is there a common mechanism of benefit for effective treatment of heart failure?

Abstract

European Journal of Heart FailureVolume 1, Issue 1 p. 31-34 EditorialFree Access Is there a common mechanism of benefit for effective treatment of heart failure? Jay N. Cohn, Corresponding Author Jay N. Cohn Department of Medicine, Cardiovascular Division, University of Minnesota Medical School, Box 508 UMHC, 420 Delaware Street SE, Minneapolis, MN, 55455 USATel.: + 1 612 625 5646; fax: + 1 612 624 2174.Search for more papers by this author Jay N. Cohn, Corresponding Author Jay N. Cohn Department of Medicine, Cardiovascular Division, University of Minnesota Medical School, Box 508 UMHC, 420 Delaware Street SE, Minneapolis, MN, 55455 USATel.: + 1 612 625 5646; fax: + 1 612 624 2174.Search for more papers by this author First published: 21 April 2005 https://doi.org/10.1016/S1388-9842(99)00002-1Citations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1CohnJN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition: editorial. Circulation 1995; 91: 2504– 2507. 2Poole-WilsonPA. Spirals, paradigms, and the progression of heart failure. J Card Failure 1996; 2: 1– 4. 3CohnJN. Drug therapy: the management of chronic heart failure. New Engl J Med 1996; 335: 490– 498. 4CohnJN JohnsonG. Heart failure with normal ejection fraction: the V-HeFT study. Circulation 1990; 81 Suppl III: 48– 53. 5CohnJN ArchibaldDG ZiescheS. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 1986; 314: 1547– 1552. 6CintronG JohnsonG FrancisG CobbF, Cohn JN (for the V-HeFT VA Cooperative Studies Group). Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993; 87: VI-17– VI-23. 7BristowMR GilbertEM AbrahamWT. (for the MOCHA Investigators). Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807– 2816. 8CohnJN LevineTB OlivariMT. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819– 823. 9LevineTB FrancisGS GoldsmithSR SimonA CohnJN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49: 1659– 1666. 10BurnettJC, Jr KaoPC HuDC. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231: 1145– 1147. 11CodyRJ HaasGJ BinkleyPF CapersQ KelleyR. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504– 509. 12FrancisGS CohnJN JohnsonG RectorTS GoldmanS, Simon A (for the V-HeFT VA Cooperative Studies Group). Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87: VI-40– VI-48. 13FletcherRD CintronGB JohnsonG OrndorffJ CarsonP, Cohn JN (for the V-HeFT VA Cooperative Studies Group). Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. Circulation 1993; 87: VI-49– VI-55. 14CohnJN JohnsonGR ShabetaiR. (for the V-HeFT VA Cooperative Studies Group). Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87: VI-5– VI-16. 15. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406– 412. 16GoldmanS JohnsonG CohnJN CintronG SmithR, Francis G (for the V-HeFT VA Cooperative Studies Group). Mechanism of death in heart failure: the vasolidator-heart failure trials. Circulation 1993; 87: VI-24– VI-31. 17MassieBM FisherSG RadfordM. Effect of amiodarone on clinical state and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 1996; 93: 2128– 2134. 18GreeneBW GrahamEL WernerJA. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmia. J Am Coll Cardiol 1983; 2: 1114– 1128. 19SinghSN FletcherRD FisherSG. (for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77– 82. 20CohnJN JohnsonG ZiescheS. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303– 310. Citing Literature Volume1, Issue1March 1999Pages 31-34 ReferencesRelatedInformation